NCT01128114 - Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Acute Bipolar Mania

Interventions

DRUG

Quetiapine fumarate (Seroquel XR)

Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.

Trial Locations (11)

Research Site, Junam

Research Site, Cheonan

Research Site, Chuncheon

Research Site, Bucheon-si

Research Site, Suwon

Research Site, Gyeongju

Research Site, Yongsan-gu

Research Site, Daejeon

Research Site, Gyungbook

Research Site, Naju

Research Site, Seoul